Additional file 1: Table S1. of SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trialChristoph Rochlitz, Ralph C. Winterhalder, Klazien Matter-Walstra et al.|Figshare|2016Cited by 0
Additional file 1: Table S1. of SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trialChristoph Rochlitz, Ralph C. Winterhalder, Martin Bigler et al.|Figshare|2016Cited by 0